drugset / Trial / NCT06728631
Candonilimab and ATRA Acid for Prevention of Oral Cancer Recurrence in Patients With OPL
Phase 2
Active not recruiting
22 enrolled
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Non-randomizedSingle-groupOpen-labelPrevention
Summary
The aim of this study is to involve high-risk patients with a history of malignant transformation in oral potentially malignant disorders. We will use a combination of Cardunil and all-trans retinoic acid for intervention. The effectiveness and safety of the combination therapy will be evaluated in the treatment of high-risk oral potentially malignant disorders, including the prevention of oral cancer recurrence and treatment of oral potentially malignant disorders. The findings of this study will provide evidence for tertiary prevention of oral cancer and the treatment of oral potentially malignant disorders.
Timeline
- Start
- 2020-06-30
- Primary completion
- 2023-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Candonilimab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Tretinoin | Small molecule | 25 mg/m2 | — |